The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

Delhi is not just breathing toxic air, but also a superbug through its air, which was found in a latest research conducted by the researchers are Jawaharlal Nehru University, published in Nature - Scientific Reports. Apart from the heavy particulate matter or the PM2.5, which are small enough to penetrate through one's bloodstream and cause blockage, Delhi's air also contains airborne bacteria, including staphylococci. The bacteria levels exceed the safety limit by 16-fold as provided by the World Health Organization (WHO).

According to scientists most of these bacteria are methicillin resistant and unaffected by multiple antibiotic classes. This has raised concerns about the hard to treat and life threatening air that people are breathing in Delhi, also responsible for causing respiratory infections. While Delhi's AQI may have improved in the past few days and come down to 'very poor' from 'severe', high levels of particulate matter still put many people at the risk of aggravated asthma and cardiovascular disease. However, the added finding of the antimicrobial resistant superbug also adds a new layer of threat to residents.

Many have left the city already due to the toxic air. Aflah Ul Haque, a 33-year-old Media and Communications PR consultant had been living in Delhi since 2017. However, in 2024, he considered to move out. While he did face difficulties to uproot himself from a metro city like Delhi, as it had become his comfort zone, it was a decision he had to take for a healthy life. Health and Me also previously reported stories of people who shifted or are actively considering shifting out of the city. Will more people consider the same move now that a superbug is found in the air? This is yet to be seen.

Read: Connection Between Migration And Pollution: People Are Leaving City To Be Away From Delhi's Toxic Air

What Did PM Modi Say About Antimicrobial Resistance?

India is already fighting a battle with antimicrobial resistance or AMR, with the breakthrough of Zaynich, a drug to treat AMR, there is hope, however, one still needs to be extra careful. On December 28, 2025, Prime Minister Narendra Modi on the 129th edition of "Mann Ki Baat", spoke about AMR. He pointed out that this is a matter of concern and cited data from the Indian Council of Medical Research (ICMR) showing that antibiotics are becoming less effective against pneumonia and urinary tract infections. He also pointed out that in India, this is a crisis due to "thoughtless and indiscriminate use of antibiotics by people".

How Was The Study That Found Superbug In Delhi's Air Conducted?

In order to understand what people might be breathing in, the researchers collected air samples from a range of everyday locations across Delhi, such as:

• Crowded market areas
• Urban slum neighborhoods
• Residential apartments
• A sewage treatment plant located within the JNU campus

Both indoor and outdoor air samples were taken during summer, monsoon and winter to track how bacterial levels and resistance patterns shifted with the seasons.

Across every setting, airborne bacteria levels were far above the World Health Organization’s recommended safe limit for microbial exposure. In some winter samples, bacterial counts exceeded 16,000 colony-forming units per cubic meter, which is more than 16 times higher than the WHO guideline.

What raised even greater concern was the type of bacteria detected. Many belonged to the Staphylococcus group, which includes strains linked to skin infections, pneumonia, bloodstream infections and illnesses commonly acquired in hospitals.

According to the researchers, a large share of the airborne bacteria were identified as methicillin-resistant staphylococci (MRS), meaning they do not respond to commonly prescribed antibiotics. Among these:

73 per cent were multidrug-resistant, showing resistance to several classes of antibiotics

Many were resistant to macrolides, beta-lactams, trimethoprim, gentamicin and other commonly used drugs

Genetic analysis confirmed the presence of antibiotic resistance genes (ARGs)

Notably, 14 out of 36 multidrug-resistant samples carried the mecA gene, a well-known marker that makes bacteria resistant to methicillin and related antibiotics.

Why Is Winter Smog Linked To Drug-Resistant Bacteria?

The study showed that levels of airborne drug-resistant bacteria were highest in winter, while monsoon rains led to a sharp drop in outdoor contamination.

Researchers point to a few likely reasons:

• Poor air movement in winter traps pollutants and microbes near ground level
• High levels of particulate matter may give bacteria surfaces to cling to and spread
• Cooler temperatures and lower humidity allow bacteria to survive longer in the air

On the other hand, rainfall during the monsoon appears to clear bioaerosols from the air, reducing bacterial concentrations outdoors.

Popular weight loss drugs have now dominated the market, especially with the US lowering its prices. In a new move, Australia now too will see, what many are calling a 'massive' reduction in the priced of Wegovy, another popular weight loss drug like Ozempic. The weight loss medicine will be subsidized, as it is set to be listed on the Pharmaceutical Benefits Scheme of Australia, or the PBS. This is for the patients with 'severe' obesity and cardiovascular diseases, which will save them thousands of dollars. However, the government warns that it will lump taxpayers with a 'very big bill'.

Health Minister Mark Butler noted that this weight loss drug will be available on the PBS for patients with an "established cardiovascular disease", which means someone who has had a heart attack or stroke, and has a BMI of 35 or higher, recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) late last year.

What Is Wegovy?

Wegovy is a glucagon-like peptide-1 or GLP-1 medication, like Ozempic, which helps to suppress the individual's appetite, thus leading to weight loss. On Friday, as reported by ABC News, Butler said, "Right now, more than 400,000 Australians are paying market prices for one of the GLP-1s, and that is as much as $4,000 or $5,000 a year, which is obviously beyond the means of many Australians." Butler said that this is not "just a health issue for us, it is also an equity issue".

Obesity Issue In Australia

As per 2022 data, around 13 per cent of Australian adults live with “severe obesity,” defined as having a BMI of 35 or higher.

There is no confirmed timeline for when the drug will be added to the PBS, but once listed, eligible patients are expected to see a sharp drop in costs. From January 1, PBS medicines have been capped at $25 per prescription, or $7.70 for concession card holders.

However, Health Minister Mark Butler acknowledged that subsidising the drug would place a “very large financial burden” on taxpayers. His office declined to provide even an estimated cost, saying clearer figures would emerge once price negotiations with manufacturer Novo Nordisk begin.

In advice released in December, the Pharmaceutical Benefits Advisory Committee (PBAC) warned of a “significant risk” that people who do not meet both eligibility criteria—especially those meeting only one—may still seek subsidized access. To manage potential costs, the committee recommended a risk-sharing arrangement with the company.

Currently, Ozempic is the only weight loss drug available on the PBS for patients with type 2 diabetes, which is what GLP-1 medications were originally in the market for.

What Are The Experts Saying?

Dr Mark Mellor, the lead clinician at Perth Weight Clinic told ABC News that the criteria to avail the medicines were "deliberately narrow" to avoid a cost blow out.

Dr Mellor said the medication is especially effective for the two identified groups because it not only aids weight loss but also helps reduce the risk of future cardiovascular problems, potentially saving lives.

“The goal is to prevent another cardiovascular event or death from heart disease,” he said, adding that providing treatment to those who are eligible and willing “simply makes sense.”

The Telangana Drugs Control Administration on Saturday released an urgent advisory asking the public to immediately stop using Almont-Kid Syrup, a medicine commonly given to children for allergies, hay fever, and asthma, after it was allegedly found to be contaminated with Ethylene Glycol (EG), a highly poisonous chemical.

In an official notice, the DCA said it received an alert from the Central Drugs Standard Control Organisation (CDSCO), East Zone, Kolkata. A laboratory analysis flagged the syrup, which contains Levocetirizine Dihydrochloride and Montelukast Sodium, as adulterated.

Telangana Issues Notice For Children’s Syrup After Toxic Adulteration Found

The Telangana Drugs Control Administration (DCA) issued a warning advising people to stop using Almont-Kid Syrup after tests allegedly found Ethylene Glycol (EG) in the product. The syrup is commonly prescribed to children to relieve allergy-related symptoms such as sneezing, runny nose, itching, swelling, nasal congestion, and watery eyes. It is also used to manage asthma and certain skin allergies.

According to the DCA notice, the alert was triggered by a communication from the Central Drugs Standard Control Organisation (CDSCO), East Zone, Kolkata, following a lab report that declared the Levocetirizine Dihydrochloride and Montelukast Sodium Syrup as adulterated.

The DCA stated, “In light of the above, the public is hereby strongly advised to immediately stop the use of the above syrup, if in possession, and report the same to the nearest Drugs Control Authority without delay.” Officials have instructed Drugs Inspectors and Assistant Directors across Telangana to immediately inform retailers, wholesalers, distributors, and hospitals to freeze any available stock of the affected batch and ensure it is not sold or dispensed under any circumstances. The DCA has also urged members of the public to report if they have the syrup and to avoid using it altogether.

What Is Ethylene Glycol?

Ethylene glycol is a colourless, odourless, and low-volatility liquid, according to Science Direct. It has a low freezing point and a high boiling point, which is why it is widely used in antifreeze and de-icing products. Ethylene glycol has a sweet taste, which increases the risk of accidental ingestion, especially among children. Experts warn that untreated ingestion of ethylene glycol can result in severe illness and can be fatal, as per Cleveland Clinic.

What Is Ethylene Glycol Poisoning?

Ethylene glycol poisoning happens when the substance is swallowed. Once ingested, it is rapidly absorbed into the body, with peak levels usually reached within one to two hours. In the first 30 minutes to 12 hours, symptoms can resemble alcohol intoxication and may include dizziness, euphoria, slurred speech, nausea, vomiting, and problems with coordination. In severe cases, this stage can progress to seizures or coma due to the chemical’s direct toxic effects on the brain.

During the next phase, typically between 12 and 36 hours, the body breaks down ethylene glycol into harmful acids such as glycolic acid. This leads to metabolic acidosis, fast heart rate, rapid breathing, low calcium levels, muscle spasms, and possible heart failure. Without timely medical treatment, this stage can be life-threatening. Between 36 and 72 hours after ingestion, kidney injury may develop as oxalate crystals form, potentially causing acute kidney failure, reduced or absent urine output, brain swelling, and long-term organ damage.

Impact Of Ethylene Glycol Poisoning

Ethylene glycol poisoning can cause serious and potentially fatal complications because its toxic byproducts affect multiple organs. Some of the key impacts, as per Mayo Clinic, include:

Brain and Nervous System Damage: In the early phase, the toxin can cause confusion similar to intoxication, seizures, and coma due to its direct effect on the nervous system. Later on, acid buildup can lead to brain swelling and encephalopathy. If untreated, this may result in permanent brain damage, stroke-like symptoms, or death.

Heart and Lung Failure: Glycolic acid can trigger severe metabolic acidosis, leading to rapid or irregular heartbeats, dangerously high or low blood pressure, and heart failure. This may progress to fluid buildup in the lungs, breathing failure with deep and rapid breaths, and eventual circulatory collapse.

Kidney Damage: The formation of oxalate crystals in the kidneys can cause acute tubular necrosis, flank pain, blood in the urine, and reduced or stopped urine production. In some cases, acute kidney injury progresses to complete kidney failure, which may be permanent and require long-term dialysis or a transplant.

Multi-Organ Collapse: Ethylene glycol disrupts normal cellular function, leading to low calcium levels, muscle spasms, tremors, and lactic acidosis. In severe and untreated cases, this can result in shock, failure of multiple organs, and death.

Long-Term Consequences: People who survive ethylene glycol poisoning may experience lasting health problems such as chronic kidney disease, nerve damage, or heart complications. Outcomes are significantly worse when treatment is delayed or when the patient develops seizures, coma, or severe acidosis.